Cognitive Decline, Cognitive Function
Conditions
Keywords
Cognitive Health, Healthy Aging
Brief summary
This study will evaluate the efficacy of 1MD Nutrition's MindMD supplement in improving and maintaining cognitive function and memory. The randomized controlled trial will include 50 healthy participants aged 50-75 years, lasting for 3 months. Participants will be randomized to receive either the test product or a placebo.
Interventions
DIETARY_SUPPLEMENTMindMD Supplement
Participants will take two capsules of the MindMD supplement once daily with their morning meal for a duration of 3 months. The supplement is designed to improve and maintain cognitive function and memory.
OTHERPlacebo
Participants will take two capsules of the placebo once daily with their morning meal for a duration of 3 months. The placebo is designed to be indistinguishable in appearance and administration from the MindMD supplement to ensure blinding.
Sponsors
Citruslabs
Scale Media Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 50-75 years * Regular experience of symptoms related to cognitive decline (e.g., forgetfulness, lack of focus, brain fog) * Generally healthy without uncontrolled chronic diseases * Willingness to avoid certain medications and supplements during the study
Exclusion criteria
* Any medical condition or treatment impacting cognitive ability Mental health or neurological disorders * Severe allergies, particularly to soy or other product ingredients * Taking blood thinning medication * Recent or planned surgeries * Major illness in the past three months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive Function and Memory Improvement | Baseline, Month 2, and Month 3 | Measurement of cognitive function and memory through Cognitive Battery Testing. The Cognitive Battery Testing includes assessments such as Polygons, Double Trouble, Feature Match, Paired Associates, Digit Span, and Spatial Planning. These assessments provide objective measurements of various cognitive functions, including processing speed, memory recall, selective attention, and executive function. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Participants' Perceptions of Cognitive Function and Memory using the Cognitive Function Questionnaire | Baseline, Month 1, Month 2, and Month 3 | Evaluation of participants' self-reported perceptions of the effect of the MindMD supplement on cognitive function and memory. This includes aspects such as focus and attentiveness, comprehension and mental clarity, learning acuity, absentmindedness, and overall quality of life. These perceptions will be measured through the Cognitive Function Questionnaire (CFQ) at specified time points: Baseline (Day 0), Month 1, Month 2, and Month 3. |
| Participants' Quality of Life | Baseline, Month 1, Month 2, and Month 3 | Assessment of participants' quality of life using the WHO-5 Well-Being Index. These assessments will be conducted at Baseline (Day 0), Month 1, Month 2, and Month 3. |
| Participants' Focus and Attentiveness | Baseline, Month 1, Month 2, and Month 3 | Evaluation of participants' focus and attentiveness using the Visual Analog Scale (VAS). These assessments will be conducted at Baseline (Day 0), Month 1, Month 2, and Month 3. |
Countries
United States
Outcome results
None listed